Get the Stockscreener App
2.12
2.30%
-0.05
Nkarta Inc stock is traded at $2.12, with a volume of 472.82K.
It is down -2.30% in the last 24 hours and up +23.98% over the past month.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
See More
Previous Close:
$2.17
Open:
$2.15
24h Volume:
472.82K
Relative Volume:
0.96
Market Cap:
$150.43M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.8833
EPS:
-2.4
Net Cash Flow:
$-114.31M
1W Performance:
-1.85%
1M Performance:
+23.98%
6M Performance:
-9.40%
1Y Performance:
-66.93%
1-Day Range:
$2.01
$2.17
1-Week Range:
$2.01
$2.32
52-Week Range:
$1.31
$6.6279
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.12 | 153.98M | 0 | -117.50M | -114.31M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
Applying Wyckoff theory to Nkarta Inc. stockAI Risk Optimized Trade Forecast Planner - Newser
Custom strategy builders for tracking Nkarta Inc.Breakout Stock Opportunities with Low Drawdown - Newser
What is Nkarta Inc. company’s growth strategyAdvanced Screener Planner For 2025 - jammulinksnews.com
Is Nkarta Inc. a growth stock or a value stockBeginner Investor Planner With Low Risk - jammulinksnews.com
Building trade automation scripts for Nkarta Inc.Stock Market Watch with Smart Filters - Newser
Is Nkarta Inc. trending in predictive chart modelsWeekly Return Plan for Conservative Traders - Newser
Detecting price anomalies in Nkarta Inc. with AIFree Real Time Trade Opportunity Alerts - Newser
What makes Nkarta Inc. stock price move sharplyPredictive Model for Intraday Swing Forecast - Newser
How Nkarta Inc. stock performs during market volatilityDaily Stock Watch Summary with Key Insights - Newser
Why Nkarta Inc. stock attracts strong analyst attentionROI Focused Watchlist with Trade Confidence - Newser
Nkarta, Inc. (NASDAQ:NKTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Is Nkarta Inc. Stock Overbought or Oversold RSI Indicator AnalysisTrade Scanner With Buy Zone Alerts Flagged - metal.it
AI Tools Suggest Nkarta Inc. May Outperform This WeekBreakout Confirmation With Entry Tracker Enabled - metal.it
What does NKTX's flat EPS in 2024 indicate for future growth? - AInvest
Published on: 2025-07-28 05:39:49 - jammulinksnews.com
What markets is ATCO.PRD expanding into Is Nkarta Inc. stock a good long term investment optionDiscover the fastest growing stocks today - jammulinksnews.com
What are analysts’ price targets for Nkarta Inc. in the next 12 monthsDiscover undervalued stocks before they soar - jammulinksnews.com
What markets is Nkarta Inc. expanding into Is BML.PRH stock a good long term investment optionRecord-breaking capital gains - jammulinksnews.com
What catalysts could drive Nkarta Inc. stock higher in 2025Explosive capital appreciation - jammulinksnews.com
When is Nkarta Inc. stock expected to show significant growthGet daily expert analysis for smarter investing - jammulinksnews.com
What is the risk reward ratio of investing in Nkarta Inc. stockGet daily updates on top-performing stocks - jammulinksnews.com
What is the dividend policy of Nkarta Inc. stockFree Technical Analysis Support - jammulinksnews.com
How Interest Rate Changes Impact Nkarta Inc. Stock PerformanceCarefully Curated High Return Stocks - Newser
Top Risks to Consider Before Buying Nkarta Inc. Stock5x Profit Potential - Newser
Nkarta Inc. Stock Analysis and ForecastConsistently superior profits - PrintWeekIndia
What drives Nkarta Inc. stock priceFree Stock Market Knowledge Sharing - Autocar Professional
What analysts say about Nkarta Inc. stockFree Advanced Stock Screener Access - Autocar Professional
How high can Nkarta Inc. stock price go in 2025Outstanding investment returns - jammulinksnews.com
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewswire
The Myth of All-American Drugs and What Trump’s Tariffs Miss About Pharma Supply Chains - MedCity News
Is Nkarta Inc. a good long term investmentFree Technical Analysis Support - Autocar Professional
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nkarta Inc Stock (NKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shook David | See Remarks |
Jan 15 '25 |
Sale |
2.20 |
8,638 |
19,004 |
190,955 |
| Levin Alyssa | See Remarks |
Jan 15 '25 |
Sale |
2.20 |
5,838 |
12,844 |
102,662 |
| Brandenberger Ralph | Chief Technical Officer |
Jan 15 '25 |
Sale |
2.20 |
7,447 |
16,383 |
124,796 |
| HASTINGS PAUL J | Chief Executive Officer |
Jan 15 '25 |
Sale |
2.20 |
17,378 |
38,232 |
319,859 |
| Hager Alicia J. | Chief Legal Officer |
Jan 15 '25 |
Sale |
2.20 |
9,584 |
21,085 |
146,735 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):